A Model for Tumor Response to Chemotherapy:An Integration of the Stem Cell and Somatic Mutation Hypotheses

References

• Goldie J H, Coldman A J. The genetic origin of drag resistance in neoplasms: Implications for systemic therapy. Cancer Res 1984; 44: 3643–3653
   PubMed Web of Science ®Google Scholar
• Ling V. Genetic basis of drug resistance in mammalian cells. Drug and Hormone Resistance in Neoplasia, N Bruchovsky, J H Goldie. CRC Press, Boca Raton, FL 1982; Vol. 1
   Google Scholar
• Goldie J H, Coldman A J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–1733
   PubMedGoogle Scholar
• Goldie J H, Coldman A J, Gudauskas G A. Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
   PubMedGoogle Scholar
• Coldman A J, Goldie J H. A model for the resistance of tumor cells to cancer chemotherapeutic agents. Math Biosci 1983; 65: 291–307
   Web of Science ®Google Scholar
• Nowell P C. Genetic instability in cancer cells: Relationship to tumors cell heterogeneity. Tumor Cell Heterogeneity Origins and Implications, A H Owens, D S Coffey, S B Baylin. Academic Press Inc., New York 1982; 351–369
   Google Scholar
• Nowell P C. Tumor progression and clonal evolution: The role of genetic instability. Chromosome Mutation and Neoplasia, J German. Alan R. Liss, New York 1983; 413–432
   Google Scholar
• Fidler I J, Poste E G. The heterogeneity of metastatic properties in malignant tumor cells and regulation of the metastatic phe-notype. Tumor Cell Heterogeneity Origins and Implications, A H Owens, D F Coffey, S B Baylin. Academic Press Inc., New York 1982; 127–146
   Google Scholar
• Hill B T. Biochemical and cell kinetic aspects to drug resistance. Drug and Hormone Resistance in Neoplasia, N Bruchovsky, J H Goldie. CRC Press, Boca Raton, Fl 1982; Vol. 1
   Google Scholar
• Luria S E, Delbruck M. Mutation of bacteria from virus sensitivity to virus resistance. Genetics 1943; 28: 491–511
   PubMedGoogle Scholar
• Siminovitch L. On the nature of hereditable variation in cultured somatic cells. Cell 1976; 7: 1–11
   PubMed Web of Science ®Google Scholar
• Skipper H E. Some thoughts regarding a recent publication by Goldie and Coldman entitled “A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate”. Booklet 9. Southern Research Institute, Birmingham, AL 1980
   Google Scholar
• DeVita V T, Jr. The relationship between tumor mass and resistance to chemotherapy. Cancer 1983; 51: 1209–1220
   PubMed Web of Science ®Google Scholar
• Schabel F M, Jr, Skipper H E, Trader M W, Laster W R, Jr, Corbett T H, Griswold D P. Concepts for controlling drug resistant tumor cells. Breast Cancer Experimental and Clinical Aspects, H T Moundren, T Palshol. Pergamon Press, Oxford 1980; 199–212
   Google Scholar
• Santoro A, Bonadonna G, Bonfant V, Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 1982; 306: 770–775
   PubMed Web of Science ®Google Scholar
• Bush R S, Hill R P. Biologic discussion augmenting radiation effects in model systems. Laryngoscope 1975; 85: 119–1133
   Google Scholar
• Bush R S, DeBoer G, Hill R P. Long term survival with gynecological cancer. Prolonged Arrest of Cancer, B A Stoll. John Wiley and Sons Inc., New York 1982; 27–58
   Google Scholar
• Buick R N, Mackillop W J. Measurement of self-renewal in culture of clonogenic cells from human ovarian carcinoma. Br J Cancer 1981; 44: 349–355
   PubMed Web of Science ®Google Scholar
• Salmon S E, Alberts D S, Meyskens F L, Jr., Durie B GM, Jones S E, Soehalen B, Young L, Chen H S, Moon T E. Clinical correlations of in vitro drug sensitivity. Cloning of Human Tumor Stem Cells, S E Salmon. Alan R. Liss, New York 1980; 223–246
   Google Scholar
• Goldie J H, Coldman A J. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 1983; 67: 923–931
   PubMedGoogle Scholar
• Schackney S E, McCormack G W, Cuchural G J, Jr. Growth rate patterns of solid tumors and their relation to responsiveness to therapy: An analytical review. Ann Intern Med 1978; 89: 107–121
   PubMed Web of Science ®Google Scholar
• Baskan F, Rosenberg R N, Vaithilingham D. Correlation of double minute chromosomes with unstable multidrug crossresistance in uptake mutants of neuroblastoma cells. Proc Natl Acad Sci USA 1981; 78: 3654–3658
   PubMed Web of Science ®Google Scholar
• Kaufman R J, Brown P C, Schimke R T. Amplified dihydrofolate reductase genes in unstable methotrexate resistant cells are associated with double minute chromosomes. Proc Natl Acad Sci USA 1979; 76: 5669–5673
   PubMed Web of Science ®Google Scholar
• Tischfield J A, Trill J J, Lee Y I, Coy K, Tylor M W. Genetic instability at the adenine phosphoribosyl transferase locus in mouse L cells. Molec Cell Biol 1982; 2: 250–257
   PubMedGoogle Scholar
• Ziegler J L, Deisseroth A B, Applebaum F R, Garw R G. Bur-kitt's lymphoma-a model for intensive chemotherapy. Semin Oncol 1977; 4: 317–323
   PubMed Web of Science ®Google Scholar
• Vaugn W P, Karp J E, Burke P J. Long chemotherapy free remissions after single cycle timed sequential chemotherapy for acute myelocytic leukemia. Cancer 1980; 45: 859–865
   PubMed Web of Science ®Google Scholar
• MacKillop W J, Ciampi A, Till J E, Buick R N. A stem cell model of human tumor growth: Implications for tumor cell clonogenic assays. JNCI 1983; 70: 9–16
   PubMed Web of Science ®Google Scholar
• Bruce W R, Vander Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 1963; 199: 79–80
   PubMed Web of Science ®Google Scholar
• Buick R N, Chang U A, Messner H A, Curtis J E, McCulloch E A. Self renewal capacity of leukemic blast progenitor cells. Cancer Res 1981; 41: 4849–4852
   PubMed Web of Science ®Google Scholar
• Tsururo T. Reversal of acquired resistance to Vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep 1983; 67: 889–894
   PubMedGoogle Scholar
• Hryniuk W, Bush H. The importance of dose intensity in the chemotherapy of breast cancer. J Clin Oncol 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors J M. A 12 week program for the treatment of advanced diffuse large cell lymphoma. Ann Intern Med 1985, in press
   PubMedGoogle Scholar